Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 20, 2019 - Issue 7-8
Submit an article Journal homepage
8,829
Views
47
CrossRef citations to date
0
Altmetric
Clinical Trials

Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial

Julian GoldPrince of Wales Hospital, The Albion Centre and Faculty of Medicine and Health, The University of Sydney, Australia, ;King's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, United Kingdom, ;Blizard Institute, Queen Mary University of London, London, United Kingdom, Correspondence[email protected]
View further author information
,
Dominic B. RoweFaculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia, View further author information
,
Matthew C. KiernanBrain and Mind Centre, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia, View further author information
,
Steve VucicDepartment of Neurology, Westmead Hospital, Sydney, Australia, View further author information
,
Susan MathersDepartment of Neurology, Calvary Health Care Bethlehem, Melbourne, Australia, View further author information
,
Ruben P. A. van EijkDepartment of Neurology, University Medical Centre Utrecht, Utrecht, Netherlands, View further author information
,
Avindra NathNational Institute of Neurological Disorders and Stroke, Section of Infections of the Nervous System, Bethesda, MD, USA, View further author information
,
Marta Garcia MontojoNational Institute of Neurological Disorders and Stroke, Section of Infections of the Nervous System, Bethesda, MD, USA, View further author information
,
Gina NoratoNational Institute of Neurological Disorders and Stroke, Section of Infections of the Nervous System, Bethesda, MD, USA, View further author information
,
Ulisses A. SantamariaNational Institute of Neurological Disorders and Stroke, Section of Infections of the Nervous System, Bethesda, MD, USA, View further author information
,
Mary-Louise RogersCentre for Neuroscience, Faculty of Medicine and Public Health, Flinders University, Adelaide, AustraliaView further author information
,
Andrea MalaspinaBlizard Institute, Queen Mary University of London, London, United Kingdom, View further author information
,
Vittoria LombardiBlizard Institute, Queen Mary University of London, London, United Kingdom, View further author information
,
Puja R. MehtaKing's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, United Kingdom, View further author information
,
Henk-Jan WestenengDepartment of Neurology, University Medical Centre Utrecht, Utrecht, Netherlands, View further author information
,
Leonard H. van den BergDepartment of Neurology, University Medical Centre Utrecht, Utrecht, Netherlands, View further author information
&
Ammar Al-ChalabiKing's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, United Kingdom, ORCID Iconhttp://orcid.org/0000-0002-4924-7712View further author information
ORCID Icon show all
Pages 595-604 | Received 09 Apr 2019, Accepted 08 Jun 2019, Published online: 08 Jul 2019

Related Research Data

Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
Source: American Society for Microbiology
The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia.
Source: Ovid Technologies (Wolters Kluwer Health)
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans
Source: Elsevier BV
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects
Source: Oxford University Press (OUP)
Retroviruses and amyotrophic lateral sclerosis.
Source: Elsevier BV
Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.
Source: Lippincott Williams & Wilkins
A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS
Source: Ovid Technologies (Wolters Kluwer Health)
Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins
Source: Springer Nature
Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis.
Source: Ovid Technologies (Wolters Kluwer Health)
A prognostic, disease progression, and pharmacodynamic biomarker in ALS
Source: Ovid Technologies (Wolters Kluwer Health)
The Neurophysiological Index in ALS.
Source: Informa UK Limited
Inhibition of human endogenous retrovirus-K by antiretroviral drugs
Source: Springer Science and Business Media LLC
Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate.
Source: Ovid Technologies (Wolters Kluwer Health)
Genomic Flexibility of Human Endogenous Retrovirus Type K
Source: American Society for Microbiology
Human Endogenous Retroviruses in Neurological Diseases
Source: HAL CCSD

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.